Bioanalysis and the Oncology Revolution
2021; Future Science Ltd; Volume: 13; Issue: 5 Linguagem: Inglês
10.4155/bio-2021-0014
ISSN1757-6199
AutoresEnaksha Wickremsinhe, Christopher James,
Tópico(s)Cell Image Analysis Techniques
ResumoBioanalysisVol. 13, No. 5 EditorialBioanalysis and the oncology revolutionEnaksha R Wickremsinhe & Christopher A JamesEnaksha R Wickremsinhe*Author for correspondence: E-mail Address: enaksha@lilly.comEli Lilly & Company, Indianapolis, IN 46285, USASearch for more papers by this author & Christopher A JamesAmgen Research, Thousand Oaks, CA 91320, USASearch for more papers by this authorPublished Online:4 Mar 2021https://doi.org/10.4155/bio-2021-0014AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: bioanalyticalco-med interferenceco-med stabilitynovel drug modalitiesoncology studiespolypharmacyselectivitystability testingReferences1. Martin-Liberal J, Hierro C, Ochoa De Olza M, Rodon J. Immuno-oncology: the third paradigm in early drug development. Target Oncol. 12(2), 125–138 (2017).Crossref, Medline, Google Scholar2. Graul AI, Pina P, Cruces E, Stringer M. The year's new drugs and biologics 2018: part I. Drugs Today (Barc.) 55(1), 35–87 (2019).Crossref, Medline, CAS, Google Scholar3. Blanco MJ, Gardinier KM. New chemical modalities and strategic thinking in early drug discovery. ACS Med. Chem. Lett. 11(3), 228–231 (2020).Crossref, Medline, CAS, Google Scholar4. Webster RM. Combination therapies in oncology. Nat. Rev. Drug Discov. 15(2), 81–82 (2016).Crossref, Medline, CAS, Google Scholar5. Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med. 8(1), 115 (2016).Crossref, Medline, Google Scholar6. Fumet J-D, Isambert N, Hervieu A et al. Evaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME). Ann. Oncol. 29(x31), 85P (2018).Google Scholar7. Masuda N, Ohtani S, Takano T et al. A randomized, 3-arm, neoadjuvant, Phase II study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1 + P), and T-DM1 + P in HER2-positive primary breast cancer. Breast Cancer Res. Treat. 180(1), 135–146 (2020).Crossref, Medline, CAS, Google Scholar8. Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small-cell lung cancer: A United States-based cost–effectiveness analysis. Cancer 125(20), 3526–3534 (2019).Crossref, Medline, CAS, Google Scholar9. Mateos M-V, Cavo M, Bladé J et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in Alcyone. Blood 134(Suppl. 1), 859 (2019).Crossref, Google Scholar10. O'malley DM, Richardson DL, Vergote IB et al. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer. Ann. Oncol. 31, S626–S627 (2020).Medline, Google Scholar11. Paller CJ, Huang EP, Luechtefeld T et al. Factors affecting combination trial success (FACTS): investigator survey results on Early-Phase Combination Trials. Front Med. (Lausanne) 6, 122 (2019).Crossref, Medline, Google Scholar12. Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications. Clin. Cancer Res. 26(21), 5557–5566 (2020).Crossref, Medline, CAS, Google Scholar13. Sicklick JK, Kato S, Okamura R et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25(5), 744–750 (2019).Crossref, Medline, CAS, Google Scholar14. Roy S, Vallepu S, Barrios C, Hunter K. Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer. J. Clin. Med. Res. 10(12), 911–919 (2018).Crossref, Medline, Google Scholar15. Kantilal K, Kantilal K, Barnett N. It's time for comprehensive polypharmacy reviews for older people with cancer. Pharm. J. 304(7933), (2020).Google Scholar16. Rao Gajula SN, Reddy GN, Reddy DS, Sonti R. Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. Bioanalysis 12(22), 1647–1664 (2020).Link, Google Scholar17. Mou S, Huang Y, Rosenbaum AI. ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates. Antibodies (Basel) 7(4), 41 (2018).Crossref, CAS, Google Scholar18. Hernandez-Alba O, Ehkirch A, Beck A, Cianférani S. Analysis of ADCs by native mass spectrometry. In: Antibody-Drug Conjugates: Methods and Protocols. Tumey LN (Ed.). Springer, NY, USA (2020).Crossref, Google Scholar19. Liu J, Li J, Tran C et al. Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry. Bioanalysis 11(21), 1967–1980 (2019).Link, CAS, Google Scholar20. Spengler M, Adler M, Niemeyer CM. Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques. Analyst 140(18), 6175–6194 (2015).Crossref, Medline, CAS, Google Scholar21. De Zwart M, Lausecker B, Globig S et al. Co-medication and interference testing in bioanalysis: a European Bioanalysis Forum recommendation. Bioanalysis 8(19), 2065–2070 (2016).Link, Google Scholar22. US FDA. Bioanalytical Method Validation Guidance for Industry (2018). https://www.fda.gov/downloads/drugs/guidances/ucm070107.PdfGoogle Scholar23. European Medicines Agency. Guideline on Bioanalytical Method Validation (2011). https://www.ema.europa.eu/en/bioanalytical-method-validationGoogle Scholar24. US FDA. M10 Bioanalytical Method Validation (2019). https://www.fda.gov/media/128343/downloadGoogle Scholar25. Lowes S, Boterman M, Doig M et al. Recommendations on bioanalytical method stability implications of co-administered and co-formulated drugs by Global CRO Council for Bioanalysis (GCC). Bioanalysis 4(17), 2117–2126 (2012).Link, CAS, Google Scholar26. Dechenne S, Yahvah K, Zimmer J. Validating stability and selectivity in the presence of co-administered compounds. Bioanalysis 11(20), 1819–1821 (2019).Link, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByNanocatalysis meets microfluidics: A powerful platform for sensitive bioanalysisTrAC Trends in Analytical Chemistry, Vol. 1582021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)Surinder Kaur, Stephen C Alley, Matt Szapacs, Amanda Wilson, Eugene Ciccimaro, Dian Su, Neil Henderson, Linzhi Chen, Fabio Garofolo, Shawna Hengel, Wenying Jian, John F Kellie, Anita Lee, John Mehl, Joe Palandra, Haibo Qiu, Natasha Savoie, Diaa Shakleya, Ludovicus Staelens, Hiroshi Sugimoto, Giane Sumner, Jan Welink, Robert Wheller, Y-J Xue, Jianing Zeng, Jinhui Zhang, Huiyu Zhou, Jian Wang, Scott Summerfield, Olga Kavetska, Lieve Dillen, Ragu Ramanathan, Mike Baratta, Arindam Dasgupta, Anna Edmison, Luca Ferrari, Sally Fischer, Daniela Fraier, Sam Haidar, Kathrin Heermeier, Christopher James, Allena Ji, Lina Luo, Gustavo Mendes Lima Santos, Noah Post, Anton I Rosenbaum, Sune Sporring, Sekhar Surapaneni, Stephen Vinter, Katty Wan, Eric Woolf, Olga Kavetska, Seongeun (Julia) Cho, Elham Kossary, Sandra Prior, Mohsen Rajabi Abhari, Catherine Soo, Yow-Ming Wang, Abbas Bandukwala, Elana Cherry, Isabelle Cludts, Soma Ghosh, Shirley Hopper, Akiko Ishii-Watabe, Susan Kirshner, Kevin Maher, Kimberly Maxfield, Joao Pedras-Vasconcelos, Yoshiro Saito, Dean Smith, Therese Solstad, Daniela Verthelyi, Meenu Wadhwa, Leslie Wagner, Günter Waxenecker, Haoheng Yan & Lucia Zhang17 May 2022 | Bioanalysis, Vol. 14, No. 9Welcome to volume 14 of BioanalysisSankeetha Nadarajah29 November 2021 | Bioanalysis, Vol. 14, No. 1Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays4 October 2021 | The AAPS Journal, Vol. 23, No. 6Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agentEnaksha R Wickremsinhe & Lisa B Lee19 April 2021 | Bioanalysis, Vol. 13, No. 9 Vol. 13, No. 5 Follow us on social media for the latest updates Metrics Downloaded 227 times History Received 17 January 2021 Accepted 17 February 2021 Published online 4 March 2021 Published in print March 2021 Information© 2021 Newlands PressKeywordsbioanalyticalco-med interferenceco-med stabilitynovel drug modalitiesoncology studiespolypharmacyselectivitystability testingAcknowledgmentsThe authors would like to thank A Wolf, P Conliffe, B Ackermann and K Cox for helpful suggestions.Financial & competing interests disclosureThe authors of this article are current employees of their affiliated organizations. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)